<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Natural</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Jyong’s $20M US IPO to help refile NDA of urological botanic drug</title>
      <description>
        <![CDATA[Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721538</guid>
      <pubDate>Tue, 24 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721538-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug</link>
    </item>
    <item>
      <title>Jyong’s $20M US IPO to help refile NDA of urological botanic drug</title>
      <description>
        <![CDATA[Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721456</guid>
      <pubDate>Wed, 18 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721456-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug</link>
    </item>
    <item>
      <title>Apimeds prices $11.5M IPO for bee venom-based therapy</title>
      <description>
        <![CDATA[Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713058</guid>
      <pubDate>Tue, 01 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713058-apimeds-prices-115m-ipo-for-bee-venom-based-therapy</link>
    </item>
    <item>
      <title>Apimeds prices $11.5M IPO for bee venom-based therapy</title>
      <description>
        <![CDATA[Apimeds Pharmaceuticals US Inc., a subsidiary of Seoul, South Korea-based Inscobee Inc., is “counting down” to an official IPO on the New York Stock Exchange with its S-1 filing showing a targeted offering of $11.5 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713024</guid>
      <pubDate>Mon, 30 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713024-apimeds-prices-115m-ipo-for-bee-venom-based-therapy</link>
    </item>
    <item>
      <title>US FDA grants fast track to Moebius-Sun’s knee OA pain injection</title>
      <description>
        <![CDATA[The U.S. FDA on Sept. 6 granted fast track designation to MM-II – a novel, non-opioid injectable candidate for knee osteoarthritis (OA) co-developed by Sun Pharmaceutical Industries Ltd. and Moebius Medical Ltd. Mumbai, India-based Sun and Tel Aviv, Israel-based Moebius agreed, under undisclosed terms, to co-develop the novel liposomal non-opioid pain therapy in an exclusive global licensing deal in 2016.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712399</guid>
      <pubDate>Tue, 10 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712399-us-fda-grants-fast-track-to-moebius-suns-knee-oa-pain-injection</link>
    </item>
    <item>
      <title>US FDA grants fast track to Moebius-Sun’s knee OA pain injection</title>
      <description>
        <![CDATA[The U.S. FDA on Sept. 6 granted fast track designation to MM-II – a novel, non-opioid injectable candidate for knee osteoarthritis (OA) co-developed by Sun Pharmaceutical Industries Ltd. and Moebius Medical Ltd. Mumbai, India-based Sun and Tel Aviv, Israel-based Moebius agreed, under undisclosed terms, to co-develop the novel liposomal non-opioid pain therapy in an exclusive global licensing deal in 2016.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712355</guid>
      <pubDate>Mon, 09 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712355-us-fda-grants-fast-track-to-moebius-suns-knee-oa-pain-injection</link>
    </item>
    <item>
      <title>Platycodin D inhibits intestinal fat absorption, reduces obesity and MASLD</title>
      <description>
        <![CDATA[Platycodin D (PD) is an oleanane-type triterpenoid saponin and one of the primary active substances isolated from the root of the Platycodon herb. Investigators from First Affiliated Hospital of Jinan University and affiliated organizations studied the effects of PD on high-fat diet-induced obesity and nonalcoholic fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease or MASLD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/710679</guid>
      <pubDate>Mon, 22 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710679-platycodin-d-inhibits-intestinal-fat-absorption-reduces-obesity-and-masld</link>
    </item>
    <item>
      <title>Isotoosendanin inhibits TNBC metastasis</title>
      <description>
        <![CDATA[Previous studies have demonstrated that the natural product isotoosendanin (ITSN) inhibited triple-negative breast cancer (TNBC) metastasis by preventing epithelial-mesenchymal transition (EMT) and lamellipodia formation regulated by the TGF-β–Smad2/3 signaling pathway in TNBC cells through directly binding to TGF-β receptor type 1 (TGF-βR1).]]>
      </description>
      <guid>http://www.bioworld.com/articles/710649</guid>
      <pubDate>Fri, 19 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710649-isotoosendanin-inhibits-tnbc-metastasis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NCI-Dividing-Breast-Cancer-Cell.webp?t=1671722892" type="image/png" medium="image" fileSize="664078">
        <media:title type="plain">Dividing breast cancer cell.</media:title>
        <media:description type="plain">A triple-negative breast cancer cell (MDA-MB-231) in metaphase during cell division. Tubulin in red; mitochondria in green; chromosomes in blue. Credit: Wei Qian, University of Pittsburgh Cancer Institute/National Cancer Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Neurotech’s NTI-164 meets endpoints in pediatric autism trial</title>
      <description>
        <![CDATA[Neurotech International Ltd.’s cannabinoid NTI-164 met the primary and secondary endpoints in a phase II/III trial in children with autism spectrum disorder. The company also reported positive top-line data for Rett syndrome in a phase I/II trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707740</guid>
      <pubDate>Wed, 17 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707740-neurotechs-nti-164-meets-endpoints-in-pediatric-autism-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/Child-drawing-with-pencil.webp?t=1713380825" type="image/jpeg" medium="image" fileSize="241307">
        <media:title type="plain">Child drawing with pencil</media:title>
      </media:content>
    </item>
  </channel>
</rss>
